Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company that discovers and develops orally bioavailable small molecule drugs targeting the A3 adenosine receptor for the treatment of cancer, liver and inflammatory diseases as well as erectile dysfunction. The company’s platform leverages the differential expression of the A3 receptor in diseased versus normal cells to create selective agonists and allosteric modulators that induce apoptosis of tumor and inflammatory cells while modulating cytokine production. Its pipeline includes Piclidenoson (CF101) for psoriasis and other inflammatory indications, Namodenoson (CF102) for hepatocellular carcinoma, metabolic dysfunction associated steatohepatitis, pancreatic cancer and erectile dysfunction, and CF602, an allosteric modulator for erectile dysfunction. Can-Fite conducts preclinical and clinical research primarily through third party contract research organizations and seeks to advance its candidates through global partnership and out licensing arrangements.
Revenue is generated almost exclusively from out licensing and distribution agreements with pharmaceutical partners that provide upfront payments, milestone payments upon regulatory or sales achievements, and royalties on net sales of the licensed products. To date the company has entered into agreements with Cipher Pharmaceuticals for Piclidenoson in Canada, Gebro Holding for Piclidenoson in Spain, Switzerland, Liechtenstein and Austria, CMS Medical for Piclidenoson and Namodenoson in China (including Hong Kong, Macau and Taiwan), Kyongbo Pharm for Piclidenoson in South Korea, Ewopharma for Piclidenoson and Namodenoson in Central Eastern Europe and Switzerland, Chong Kun Dang Pharmaceuticals for Namodenoson in South Korea, and Vetbiolix for Piclidenoson in the veterinary osteoarthritis market for dogs and cats. These arrangements supply the bulk of the company’s cash inflows, as no product has yet been commercialized and therefore no direct product sales are recorded.
Can-Fite occupies a niche within the competitive biopharmaceutical landscape by focusing on the A3 adenosine receptor, a target that is over expressed in pathological cells such as tumors and inflammatory cells while showing low expression in healthy tissue. This selectivity offers a potential safety and efficacy advantage over many existing therapies that are associated with higher toxicity or require intravenous administration. In the psoriasis market, the company competes with large biologics manufacturers such as Amgen, Janssen, Eli Lilly, AbbVie, Novartis and Pfizer, but argues that Piclidenoson’s oral dosing, favorable safety profile and low cost of goods position it favorably against injectable agents. In hepatocellular carcinoma and related liver indications, competitors include Bayer, Exelixis, Merck, Roche, AstraZeneca and Novartis, yet Namodenoson’s orphan drug and Fast Track designations, oral administration and liver protective effects differentiate it from the limited approved options. For erectile dysfunction, the company faces established PDE5 inhibitor makers such as Pfizer and Eli Lilly, but claims CF602’s mechanism, which enhances endogenous adenosine signaling, may provide benefits in diabetic populations where current drugs are less effective. Overall, Can‑Fite’s competitive strengths lie in its proprietary A3AR focused chemistry, early‑stage clinical data supporting safety and activity, and a partnership driven business model that reduces the need for internal manufacturing and sales infrastructure.
The company’s customer base consists primarily of pharmaceutical and biotechnology firms that license its drug candidates for further development, regulatory approval, manufacturing and commercialization in defined geographic territories. Specific partners include Cipher Pharmaceuticals (Canada), Gebro Holding (Spain, Switzerland, Liechtenstein and Austria), CMS Medical (China, Hong Kong, Macau and Taiwan), Kyongbo Pharm Co. Ltd. (South Korea), Ewopharma AG (Central Eastern Europe and Switzerland), Chong Kun Dang Pharmaceuticals (CKD) (South Korea) and Vetbiolix SAS (France) for the veterinary osteoarthritis indication. These entities provide upfront, milestone and royalty payments in exchange for exclusive distribution or development rights, and they represent the principal counterparties with which Can‑Fite conducts its revenue generating activities.